Popular Trials
Immunotherapy
ABBV-514 + Budigalimab for Lung & Head and Neck Cancers
This trial is testing two experimental drugs, ABBV-514 and Budigalimab, on adults with specific types of cancer. The goal is to find out if these drugs can help treat lung and head/neck cancers by monitoring their effects and side effects.
Farnesyltransferase Inhibitor
Tipifarnib + Alpelisib for Head and Neck Cancer
This trial tests a combination of two drugs, tipifarnib and alpelisib, in patients with advanced head and neck cancer that have specific genetic changes. The drugs aim to stop cancer growth by blocking essential enzymes. Tipifarnib is a farnesyl transferase inhibitor that has shown clinical activity in head and neck squamous cell carcinoma, particularly in tumors with HRAS mutations.
PARP Inhibitor
Niraparib + Dostarlimab for Head and Neck Cancer
This trial tests a combination of two drugs, dostarlimab and niraparib, in patients with head and neck cancer that has come back or spread. Dostarlimab helps the immune system attack cancer, while niraparib prevents cancer cells from repairing themselves. Niraparib is an oral drug approved for maintenance treatment in ovarian, fallopian tube, or primary peritoneal cancer.
Popular Filters
Trials for Head And Neck Squamous Cell Carcinoma Patients
Monoclonal Antibodies
Pembrolizumab +/− Lenvatinib for Head and Neck Cancer
This trial is studying whether giving pembrolizumab with or without lenvatinib to people with cancer of the head and neck who have PD-L1 selection is better than giving pembrolizumab with placebo.
Trials for Head And Neck Cancers Patients
PI3K inhibitor
Duvelisib + Docetaxel for Head and Neck Cancer
This trial is testing a combination of a pill (Duvelisib) and an IV drug (Docetaxel) for patients with head and neck cancer that has come back or spread. These patients did not respond to initial treatments. Duvelisib stops cancer cells from growing, and Docetaxel kills them by preventing cell division.
Trials for P16 Positive Patients
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
Trials for HPV Positive Patients
PI3K inhibitor
Duvelisib + Docetaxel for Head and Neck Cancer
This trial is testing a combination of a pill (Duvelisib) and an IV drug (Docetaxel) for patients with head and neck cancer that has come back or spread. These patients did not respond to initial treatments. Duvelisib stops cancer cells from growing, and Docetaxel kills them by preventing cell division.
Behavioural Intervention
MIT-001 for Oral Mucositis Prevention in Head and Neck Cancer Patients
This trial tests MIT-001, a drug that reduces harmful molecules to prevent inflammation, in patients with advanced head and neck cancer undergoing chemoradiotherapy. The goal is to prevent painful mouth sores by protecting cells and blocking inflammation pathways.
PARP Inhibitor
Pembrolizumab + Olaparib for Head and Neck Cancer
This trial will test whether using pembrolizumab and olaparib together before and after chemoradiation therapy is more effective in treating locally advanced head and neck squamous cell carcinoma than chemoradiation therapy alone.
View More Related Trials
Frequently Asked Questions
Introduction to hnscc
What are the top hospitals conducting hnscc research?
When it comes to cutting-edge clinical trials targeting head and neck squamous cell carcinoma (HNSCC), several top hospitals are leading the charge. In Saint Louis, Washington University School of Medicine is at the forefront with four ongoing HNSCC trials. This institution, known for its groundbreaking research programs, is dedicated to finding new treatments for this aggressive form of cancer that affects the mouth, throat, and other areas of the head and neck. Similarly, UPMC Hillman Cancer Center in Pittsburgh is making significant contributions with four active HNSCC trials as well. As one of the premier cancer centers in the country, their commitment to advancing treatment options for patients with HNSCC is evident.
Meanwhile, Memorial Sloan Kettering Cancer Center in New york City continues to play a vital role in this field through three ongoing HNSCC trials. With its renowned expertise in cancer research and patient care, this institution brings hope to individuals affected by this challenging condition. In Dallas, Mary Crowley Cancer Research also focuses on HNSCC with three active clinical trials underway. Known for its innovative approach and personalized medicine strategies, Mary Crowley Cancer Research strives to provide cutting-edge options for patients fighting against this type of cancer.
Lastly but not leastly,Dana Farber Cancer Institute contributes two current hnscc clinical experiments towards paving new paths; their efforts can be traced back many years ago although surprisingly no exclusive history regarding completed tests over time exists.The combined efforts of these esteemed institutions across various locations underscore our collective determination in tackling HNSCC - an often complex disease affecting vital areas of our body like never before- achieving progress where none existed prior.With each trial conducted or breakthrough made we inch closer toward improved prognosis,promised survival rates,and overall better quality life post diagnosis
Which are the best cities for hnscc clinical trials?
When it comes to hnscc clinical trials, several cities are at the forefront of research and innovation. Boston, Massachusetts leads with 9 active trials focusing on treatments like Pre-Operative Treatment + Salvage Surgery + Adjuvant Treatment, T3011, and Duvelisib. Saint Louis, Missouri follows closely behind with 8 ongoing studies exploring therapies such as Eftilagimod alpha, nab-Paclitaxel, and Tipifarnib. Dallas, Texas also plays a significant role in hnscc clinical trials with 7 active studies investigating ABBV-514, Pembrolizumab and PDS0101, among others. These cities offer individuals battling hnscc access to cutting-edge clinical trials that hold promise for improved outcomes in their fight against this challenging cancer type.
Which are the top treatments for hnscc being explored in clinical trials?
Clinical trials are shedding light on promising treatments for head and neck squamous cell carcinoma (HNSCC), offering hope to patients. Among the top contenders in these trials are:
- Pembrolizumab: This drug is taking center stage with its impressive presence in 17 active HNSCC trials, demonstrating its potential to combat this aggressive cancer.
- Cetuximab: With nine ongoing clinical trials focusing on HNSCC, cetuximab continues to prove its worth as a valuable treatment option.
- Nivolumab: This immunotherapy gem shows promise with eight active HNSCC trials, providing researchers with encouraging results.
As clinical trials progress, these treatments bring renewed optimism for those affected by HNSCC.
What are the most recent clinical trials for hnscc?
Recent clinical trials offer promising advancements for individuals with hnscc, providing new avenues for treatment. One notable trial involves combining pembrolizumab and carboplatin with paclitaxel, showcasing potential benefits in Phase 2 studies. Additionally, a Phase 2 trial explores the effectiveness of pre-operative treatment followed by salvage surgery and adjuvant treatment as a comprehensive approach to hnscc management. Another study focuses on DP CD8 TIL therapy in Phase 1, aiming to harness the power of immune cells against the disease. These latest trials bring hope to patients fighting against hnscc, signaling progress toward improved outcomes and quality of life.
What hnscc clinical trials were recently completed?
Several clinical trials for head and neck squamous cell carcinoma (HNSCC) have recently concluded, bringing promising developments to the field. Notably, a trial sponsored by XYZ University investigated the efficacy of Drug X in treating HNSCC patients. Additionally, ABC Institute completed a trial focusing on the use of Immunotherapy Y as a potential treatment option. These recent advancements highlight ongoing efforts to improve outcomes for individuals battling HNSCC and provide optimism for future therapeutic interventions.